Flarin (lipid ibuprofen) versus standard of care for acute hypoxaemic respiratory failure in COVID-19

Phase 4, randomised trial in coronavirus disease 2019 (COVID-19), Acute hypoxaemic respiratory failure (AHRF) and anoxemia comparing Flarin (lipid ibuprofen) plus standard of care with Standard of care alone (2 arms). Primary endpoint: Disease progression prior to Day 14. Status: unknown.